Search results | warner chilcott

Reports

Partnering Agreements with Warner Chilcott

This report provides all the information you require to better understand Warner Chilcott and its partnering interests and activities over the past seven years.

Insights

Warner Chilcott

Warner Chilcott is a top pharmaceutical company based in Dublin, Ireland

Warner Chilcott: Company Profile

Warner Chilcott, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Actavis and Warner Chilcott in pharma merger talks

Actavis confirmed that it has entered into early stage discussions with Warner Chilcott regarding a potential pharma merger of the two companies

Warner Chilcott Luring Drug Buyers With Most Free Cash: Real M&A

Warner Chilcott offers potential acquirers the chance to buy a company in a M&A deal, that throws off more cash from selling contraceptives and colitis treatments than any specialty drugmaker in the world

Merger & acquisition: Warner Chilcott to explore sale of company

Specialty pharmaceutical company Warner Chilcott Plc said it would explore strategic options, including preliminary talks with potential buyers, sending its shares up as much as 24 percent to strike a potential merger & acquisition deal

M&A trends: Warner Chilcott Said to Consider Options After Interest

Warner Chilcott is weighing options including a possible M&A after receiving interest from strategic and private-equity buyers, according to people with knowledge of the matter. The shares jumped in early trading

Pfizer is in talks to acquire Actavis

Pfizer Inc. has approached Actavis with a possibility to acquire the company.

Is Pfizer’s next acquisition target, Actavis?

Bloomberg reports, Pfizer is looking at Actavis, the generics maker with a new home address in Ireland, among other targets.

A review of the Top 50 Pharma companies of 2014

The 2014 top 50 Pharma company list is out, with an interesting number of movers and shakers By Alamelu Elango

Top Life Science M&A Deals and Trends in 2013

With over 450 deals announced, 2013 was a big year for mergers and acquisitions in the life sciences

Events

Sorry, your search returned no results.


Deals

Warner Chilcott in $4.4 billion loan financing and debt financing

Warner Chilcott is in market with $4.4 billion in loan financing and debt financing following the company’s acquisition by drug manufacturer Actavis.

Actavis acquires Warner Chilcott in $8.5 billion megadeal

Actavis and Warner Chilcott have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion

Actavis and Warner Chilcott in pharma merger talks

Actavis confirmed that it has entered into early stage discussions with Warner Chilcott regarding a potential pharma merger of the two companies

Merger & acquisition: Warner Chilcott to explore sale of company

Specialty pharmaceutical company Warner Chilcott Plc said it would explore strategic options, including preliminary talks with potential buyers, sending its shares up as much as 24 percent to strike a potential merger & acquisition deal

M&A trends: Warner Chilcott Said to Consider Options After Interest

Warner Chilcott is weighing options including a possible M&A after receiving interest from strategic and private-equity buyers, according to people with knowledge of the matter. The shares jumped in early trading

Warner Chilcott announces acquisition of patent portfolio from AGI Therapeutics

Warner Chilcott has announced that it has completed the acquisition of a portfolio of patents from AGI Therapeutics plc for a purchase price of approximately $0.3 million.

Warner Chilcott in Amendment to Actonel collaboration with Sanofi-Aventis

Warner Chilcott will take full operational control over the promotion, marketing and R&D decisions for Actonel in the United States and Puerto Rico, and will assume responsibility for all associated costs relating to those activities.

Warner Chilcott affirms global marketing and collaboration agreement with Sanofi-Aventis

Warner Chilcott announced that Sanofi-Aventis U.S. LLC has elected not to exercise its right to put its interest in the global marketing and collaboration agreement (the “Marketing Agreement”). As previously disclosed, Warner Chilcott’s acquisition of the global branded prescription pharmaceuticals business of The Procter & Gamble Company (“P&G”) on October 30, 2009 (the “PGP Acquisition”), more »

Warner Chilcott to acquire P&G pharma division

Procter & Gamble and Warner Chilcott announced an agreement for the sale of P&G’s global pharmaceuticals business to Warner Chilcott for an up-front cash payment of $3.1 billion.

Actavis signs settlement pharma deals

Warner chilcott, a subsidary of big pharma Actavis, has reached a settlement pharma deals agreement for Asacol tablets.